Patents Assigned to National Cancer Center
  • Patent number: 10768179
    Abstract: It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: September 8, 2020
    Assignees: National Cancer Center, Daiichi Sankyo Company, Limited
    Inventors: Takashi Kohno, Hideaki Ogiwara, Yuichi Tominaga, Saito Higuchi
  • Patent number: 10765804
    Abstract: The present invention relates to an injection device for endoscopy, and provides: a feature of inserting a needle for endoscopy into a tissue, in a state of holding a body tissue, which is a region to receive an injection, and then injecting an injection solution thereinto; and a feature enabling stanching of the bleeding region if bleeding occurs. That is, tissue is held by holding forceps and a needle is inserted thereinto, corresponding to a series of operations from a state in which the needle is accommodated between the holding forceps for holding the tissue, and then an injection solution is injected into the tissue through the needle. In addition, a bleeding region is stanched by the heat transferred to the holding forceps without using a separate hemostat if bleeding occurs during the operation.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: September 8, 2020
    Assignee: NATIONAL CANCER CENTER
    Inventors: Dae Kyung Sohn, Kwang Gi Kim, Na Ri Yang
  • Publication number: 20200276163
    Abstract: A carcinogenesis inhibitor having no side effect and having an excellent effect by oral administration. A carcinogenesis inhibitor containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an active ingredient shows an inhibiting action for polyp formation and for cell proliferation, and has no side effect and highly safe whereby it is very highly useful as a pharmaceutical agent and a food such as supplement which prevent the occurrence and progress of cancer, inhibits the recurrence and metastasis of cancer and further achieves the therapeutic effect.
    Type: Application
    Filed: June 12, 2018
    Publication date: September 3, 2020
    Applicants: NATIONAL CANCER CENTER, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Michihiro MUTOH, Yurie KUROKAWA, Gen FUJII, Shingo MIYAMOTO
  • Publication number: 20200263184
    Abstract: The present invention relates to a technology for using a malate-aspartate shuttle (MAS) inhibitor as an agent for treating cancer. More particularly, provided is a pharmaceutical composition for preventing or treating cancer, containing, as an active ingredient, phenyl succinic acid, methyl malonic acid, N-(1-pyrenyl)maleimide and phthalonic acid, which are MAS inhibitors, or a mixture of the MAS inhibitor and an anticancer drug.
    Type: Application
    Filed: April 13, 2018
    Publication date: August 20, 2020
    Applicant: NATIONAL CANCER CENTER
    Inventor: Soo Youl KIM
  • Publication number: 20200255910
    Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 13, 2020
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoshi KONDOU, Hitoshi NOBUMASA, Satoko KOZONO, Hiroko SUDO, Junpei KAWAUCHI, Takahiro OCHIYA, Nobuyoshi KOSAKA, Makiko ONO, Kenji TAMURA
  • Publication number: 20200246634
    Abstract: A body-insertable device having an adjustable radiation emission direction and radiation emission range, which includes a first outer body extending to be long and an accommodation space having a first accommodation space and a second accommodation space having different distances to the first outer body.
    Type: Application
    Filed: August 27, 2018
    Publication date: August 6, 2020
    Applicant: NATIONAL CANCER CENTER
    Inventors: Young Kyung LIM, Ui Jung HWANG, Young Moon GOH, Hak Soo KIM, Dong Ho SHIN, Se Byeong LEE, Jong Hwi JEONG, Joo Young KIM, Tae Hyun KIM
  • Patent number: 10730935
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: August 4, 2020
    Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.
    Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
  • Publication number: 20200239474
    Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 30, 2020
    Applicants: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, NATIONAL CANCER CENTER, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Hwan Geun CHOI, Jong Bae PARK, Eunhwa KO, Jung Beom SON, Joong-heui CHO, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Nam Doo KIM, Yunho LEE, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Jae Hyun BAE, Eunmi HONG, Tae-ho JANG, Sang Bum KIM, Seung Hoon LEE, Do-Hyun NAM
  • Patent number: 10717781
    Abstract: The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: July 21, 2020
    Assignees: National Cancer Center, Chugai Seiyako Kabushiki Kaisha
    Inventors: Shuichi Mitsunaga, Atsushi Ochiai
  • Publication number: 20200216909
    Abstract: It is intended to provide highly sensitive and specific, rapid, and convenient method for evaluating a risk of hepatocellular carcinoma. The method for evaluating a risk of hepatocellular carcinoma comprises: (1) amplifying bisulfite-treated DNA derived from a liver tissue of a subject, wherein the DNA comprises a CpG site of an exon region of MGRN1 gene; (2) subjecting the obtained amplification product to ion exchange chromatography; and (3) determining whether or not the DNA is DNA obtained from a subject having a high risk of development of hepatocellular carcinoma on the basis of a peak shape of a detection signal of the chromatography.
    Type: Application
    Filed: August 23, 2018
    Publication date: July 9, 2020
    Applicants: NATIONAL CANCER CENTER, SEKISUI MEDICAL CO., LTD.
    Inventors: Yae KANAI, Eri ARAI, Takuya YOTANI, Ei-ichiro SUNAMURA
  • Publication number: 20200216914
    Abstract: The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Junpei KAWAUCHI, Hitoshi NOBUMASA, Satoko KOZONO, Satoshi KONDOU, Hiroko SUDO, Atsushi OCHIAI, Motohiro KOJIMA
  • Patent number: 10695039
    Abstract: The following description provides a biotissue sampling apparatus comprising a housing, a firing button configured on a rear-end of the housing; a tube with an aspirating hole configured to inject medicine in a tissue according to a longitudinal direction of a lower end and extended from a front-end of a housing; and a needle assembly that may move from the tube to a biopsy region by a button thereby cut a solid tissue and store or aspire a fluid tissue.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: June 30, 2020
    Assignee: NATIONAL CANCER CENTER
    Inventors: Hyun Guy Kang, Kwang Gi Kim, Na Ri Yang, Sang Bong Lee
  • Publication number: 20200199684
    Abstract: In order to provide a method for detecting an unfavorable prognostic risk of renal cell carcinoma easily with quite high sensitivity and specificity, a methylome analysis was performed on normal renal tissues, and non-cancerous tissues and renal cell carcinomas derived from patients with renal cell carcinomas. The result revealed that it was possible to detect an unfavorable prognostic risk of renal cell carcinoma by detecting a DNA methylation level at at least one CpG site of FAM150A, GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC, WNT3A, TRH, FAM78A, ZNF671, SLC13A5, and NKX6-2 genes.
    Type: Application
    Filed: December 10, 2019
    Publication date: June 25, 2020
    Applicant: NATIONAL CANCER CENTER
    Inventors: Yae KANAI, Eri ARAI, Ying TIAN
  • Publication number: 20200199688
    Abstract: An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.
    Type: Application
    Filed: March 3, 2020
    Publication date: June 25, 2020
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoshi KONDOU, Hitoshi NOBUMASA, Satoko KOZONO, Hiroko SUDO, Junpei KAWAUCHI, Takahiro OCHIYA, Nobuyoshi KOSAKA
  • Publication number: 20200190601
    Abstract: This invention relates to a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, comprising measuring the miRNA(s) in vitro.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 18, 2020
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoko KOZONO, Hitoshi NOBUMASA, Satoshi KONDOU, Hiroko SUDO, Junpei KAWAUCHI, Atsushi OCHIAI, Motohiro KOJIMA
  • Publication number: 20200190600
    Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.
    Type: Application
    Filed: February 7, 2020
    Publication date: June 18, 2020
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoshi KONDOU, Hitoshi NOBUMASA, Satoko KOZONO, Hiroko SUDO, Junpei KAWAUCHI, Atsushi OCHIAI, Motohiro KOJIMA
  • Publication number: 20200182897
    Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.
    Type: Application
    Filed: February 25, 2020
    Publication date: June 11, 2020
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Hiroko SUDO, Hitoshi NOBUMASA, Satoko KOZONO, Satoshi KONDOU, Junpei KAWAUCHI, Atsushi OCHIAI, Motohiro KOJIMA
  • Publication number: 20200172984
    Abstract: It is intended to provide a kit or a device for the detection of colorectal cancer and a method for detecting colorectal cancer. The present invention provides a kit or a device for the detection of colorectal cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting colorectal cancer, comprising measuring the miRNA in vitro.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 4, 2020
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoko KOZONO, Hitoshi NOBUMASA, Satoshi KONDOU, Hiroko SUDO, Junpei KAWAUCHI, Atsushi OCHIAI, Motohiro KOJIMA
  • Publication number: 20200170485
    Abstract: An information processing apparatus (2000) detects an abnormal region (30) from a predetermined range (16) of a video frame (14). The information processing apparatus (2000) determines whether a predetermined condition is satisfied in a case where the abnormal region (30) is detected from the predetermined range (16) of a certain video frame (14) and the abnormal region (30) is not detected from the predetermined range (16) of a predetermined video frame (14) generated later than the video frame (14). In a case where the predetermined condition is not satisfied, the information processing apparatus (2000) performs a predetermined notification.
    Type: Application
    Filed: May 18, 2018
    Publication date: June 4, 2020
    Applicants: NEC Corporation, National Cancer Center
    Inventors: Ikuma TAKAHASHI, Maki SANO, Motoyasu OKUTSU, Chiemi TANAKA, Masahiro SAIKOU, Hitoshi IMAOKA
  • Patent number: 10656058
    Abstract: The present invention relates to a material for aggregating blood cells, used in the preparation of a paraffin block for diagnosing circulating tumor cells (CTCs), and a method for preparing a paraffin block using the same, and more specifically, to a method for detecting CTCs present in the blood through blood sample collection in the preparation of a paraffin block from CTCs, which are present in a very small amount in the blood. The present invention is non-invasive and simple, and thus is very useful for the diagnosis of cancer recurrence and metastatic cancer and for prognosis prediction, and can be a remarkable breakthrough in cancer treatment through the analysis of the onset, metastasis and recurrence mechanisms of cancer.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: May 19, 2020
    Assignee: NATIONAL CANCER CENTER
    Inventors: Hee Jin Chang, Sun Young Kim, Ji Yeon Baek, Hyun Yang Yeo